Serina Therapeutics Stock Today
| SER Stock | 4.79 0.64 15.42% |
Performance0 of 100
| Odds Of DistressOver 81
|
Serina Therapeutics is selling at 4.79 as of the 17th of December 2024; that is 15.42 percent increase since the beginning of the trading day. The stock's lowest day price was 4.32. Serina Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Serina Therapeutics symbol was changed from AGE on 27th of March 2024. The performance scores are derived for the period starting the 17th of November 2024 and ending today, the 17th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of November 2018 | Category Healthcare | Classification Health Care |
Serina Therapeutics is entity of United States. It is traded as Stock on NYSE MKT exchange. The company has 8.88 M outstanding shares of which 27.52 K shares are at this time shorted by investors with about 1.73 days to cover. More on Serina Therapeutics
Moving together with Serina Stock
Moving against Serina Stock
Serina Stock Highlights
| Older Symbol | AGE | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Executive Chairman | Balkrishan Gill | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [STERLING RES, STERLING RES (SER.SG), STERLING RES - Frankfurt Stock Exchang, Serodus ASA] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Serina Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Serina Therapeutics' financial leverage. It provides some insight into what part of Serina Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Serina Therapeutics (SER) is traded on NYSE MKT Exchange in USA. It is located in 601 Genome Way, Huntsville, AL, United States, 35806 and employs 9 people. Serina Therapeutics was previously known as AgeX Therapeutics and was traded on NYSE MKT Exchange under the symbol AGE. Serina Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 57.2 M. Serina Therapeutics runs under Biotechnology sector within Health Care industry. The entity has 8.88 M outstanding shares of which 27.52 K shares are at this time shorted by investors with about 1.73 days to cover.
Serina Therapeutics generates negative cash flow from operations
Check Serina Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Serina Therapeutics is USD57.2 Million. Serina Therapeutics maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Serina Ownership Details
Serina Therapeutics Historical Income Statement
Serina Stock Against Markets
Serina Therapeutics Corporate Executives
Elected by the shareholders, the Serina Therapeutics' board of directors comprises two types of representatives: Serina Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Serina. The board's role is to monitor Serina Therapeutics' management team and ensure that shareholders' interests are well served. Serina Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Serina Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Bentley | Chief CoFounder | Profile | |
| Milton Harris | CoFounder Board | Profile |
Additional Tools for Serina Stock Analysis
When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.